He thinks its profit growth is accelerating. Marsico believes worries about ill side effects from Warner's new diabetes medicine, Rezulin, are overblown. They're saying that this drug is a life-changing drug for diabetics. As for Lilly, Marsico is banking on surprisingly good earnings flowing from Evista, a drug recently approved for osteoporosis. Evista is due to reach pharmacies this month.
People think it's too expensive.
They don't think it can continue to grow. They haven't done the work, and it's hard to do the work. It's hard to look at 16 different divisions at GE and really understand what they're doing. I think that the bad news is kind of out on Boeing, and the backlog remains very strong. In piloting his own funds, Marsico will encounter a stiffer headwind than he did at Janus.